Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 64, Issue 5, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02303-19
Keywords
tedizolid; daptomycin; E. faecalis; E. faecium; MRSA/VRSA; experimental endocarditis; enterococci; staphylococci
Categories
Funding
- Merck, Inc.
- NIAID [R21AI133289-01A1]
- [K24-AI121296]
- [R01AI134637]
- [R21AI143229]
Ask authors/readers for more resources
Tedizolid (TZD) and daptomycin (DAP) were assessed in a rat endocarditis model against Enterococcus faecalis, Enterococcus faecium (resistant to vancomycin and ampicillin), and Staphylococcus aureus. As a monotherapy, TZD for 5 days was not effective in a comparison with no-treatment controls, while DAP for 5 days was significantly effective against these bacteria. Step-down therapy (DAP for 3 days followed by TZD for 2 days) was as effective as DAP for 5 days and was comparable to 3 days of DAP plus ceftriaxone against all bacteria and to 3 days of DAP plus gentamicin against E. faecalis OG1RF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available